Published in final edited form as:

Biochemistry. 2009 June 9; 48(22): 4720–4727. doi:10.1021/bi900037s.

Myelin basic protein binds to and inhibits the fibrillar assembly of A β 42 in-vitro[†]

Michael D. Hoos[‡], Mahiuddin Ahmed[§], Steven O. Smith[§], and William E. Van Nostrand^{*,‡}

Department of Medicine and the Center for Structural Biology, Stony Brook University, Stony Brook, New York

Abstract

The deposition of amyloid β -protein (A β) fibrils into plaques within the brain parenchyma and along cerebral blood vessels is a hallmark of Alzheimer's disease. A β peptides are produced through the successive cleavage of the A β precursor protein by β and γ -secretase, producing peptides of between 39 and 43 amino acids in length. The most common of these are A β 40 and A β 42, the first of which being the most abundant. A β 42 is more fibrillogenic than A β 40 and has been implicated in early A β plaque deposition. Our previous studies determined that myelin basic protein (MBP) was capable of inhibiting fibril formation of a highly fibrillogenic A β peptide containing both E22Q (Dutch) and D23N (Iowa) mutations associated with familial forms of cerebral amyloid angiopathy [Hoos et al. 2007 *J. Biol. Chem.* 282:9952–9961]. In the present study we show through a combination of biochemical and ultrastructural techniques that MBP is also capable of inhibiting the β -sheet fibrillar assembly of the normal A β 42 peptide. These findings suggest that MBP may play a role in regulating the deposition of A β 42 and thereby also may regulate the early formation of amyloid plaques in Alzheimer's disease.

Deposits of amyloid β peptides (A β) into plaques in the brain parenchyma and cerebrovasculature are prominent features of Alzheimer's disease (AD) and other related disorders (1). A β is derived through the sequential proteolysis of the amyloid β precursor protein (A β PP) by β and γ -secretase (2–5). These cleavages produce A β peptides of between 39 and 43 amino acids with the most abundant being A β 40 and A β 42 (6). A β peptides exhibit a high propensity to self-assemble into β -sheet containing oligomeric forms and fibrils (7). It has been shown that the oligomerization and deposition of A β 42 likely precedes and, possibly, seeds deposition of A β 40 in amyloid plaques and cerebral vascular lesions leading to neurodegeneration and dementia (8–10). Elevated levels of soluble A β 42 have also been shown to increase the risk of developing AD pathology (10). For these reasons it is important to understand the nature of A β 42 in the CNS and how it interacts with other components of healthy and diseased brain.

[†]This work was supported by grants from the Alzheimer's Association (IIRG-06-26805), the Cure Alzheimer's Fund, Collaborative MS Research Center Award, and National Institutes of Health (RO1-AG027317).

^{*}To whom correspondence should be addressed: Dept. of Medicine, HSC T-15/083, Stony Brook University, Stony Brook, NY 11794-8153. Tel.: 631-444-1661; Fax: 631-444-2560; William.VanNostrand@stonybrook.edu.

[‡]Department of Medicine, Stony Brook University.

[§]Center for Structural Biology, Stony Brook University.

Cerebral amyloid angiopathy (CAA), a condition prevalently found in AD, is characterized by fibrillar A β deposition within and along primarily small and medium-sized arteries and arterioles of the cerebral cortex and leptomeninges and in the cerebral microvasculature (7, 11, 12). Familial forms of CAA are caused by specific point mutations within the A β sequence of the A β PP gene (13–18). The most recognized example of familial CAA is the Dutch-type resulting from an E22Q substitution in A β , (13, 14, 19). Another more recently identified form of familial CAA is the Iowa-type D23N substitution in A β (18). *In vitro* these familial forms of A β exhibit an increased propensity to form amyloid fibrils when compared to wild-type A β 40 (A β 40WT) (20–24). Including each of these mutations together in the same A β peptide (A β 40DI) further enhances the fibrillogenic and pathogenic properties *in vitro* (24). In a recent study using a combination of biochemical assays and high resolution microscopy techniques, we demonstrated that myelin basic protein (MBP) bound preferentially to the more fibrillogenic A β 40DI over A β 40WT (25). Furthermore, we showed that MBP effectively inhibits the fibrillar assembly of A β 40DI. We postulated that MBP might play a role in the regulation of familial CAA mutant A β fibrillogenesis. However, with the growing understanding of the importance of A β 42WT to disease processes such as AD and CAA, we examined if MBP can act in a similar fashion on this more fibrillogenic wild-type A β peptide as well.

In the present study we show that MBP binds to A β 42WT *in-vitro*. Using a combination of biochemical assays and high resolution microscopy, we demonstrate that MBP impedes β -sheet formation and potentially inhibits A β 42WT fibril formation. These findings lead us to postulate that endogenous MBP may play a role in regulating the fibrillar assembly and deposition of A β 42WT in Alzheimer's disease and other related conditions.

MATERIALS AND METHODS

Reagents and Chemicals

A β 42 and A β 40 peptides were synthesized by solid-phase Fmoc (9-fluorenylmethoxycarbonyl) amino acid chemistry, purified by reverse phase high performance liquid chromatography, and structurally characterized as previously described (26). N-terminally biotinylated A β 42 peptide was purchased from American Peptide Company (Sunnyvale, CA). Scrambled A β 42 peptide was purchased from AnaSpec (San Jose, CA). Eosinophil cationic protein (ECP) was purchased from Innovative Research (Novi, MI). A β 42 peptides were initially prepared in hexafluoroisopropanol, lyophilized, and resuspended in either dimethylsulfoxide (Me₂SO) or 100 mM NaOH as previously described (27). Purified human MBP (purchased from Chemicon International, Temecula, CA) was resuspended in 20mM sodium acetate, 100mM sodium chloride, pH 4.0, dialyzed into phosphate-buffered saline (PBS) and stored at –70°C at 1 mg/ml. Purified bovine lactalbumin and thioflavin-T were purchased from Sigma-Aldrich (St. Louis, MO). The anti-A β mAb 3D6 was generously provided by Lilly Research Laboratories (Indianapolis, IN). Anti-MBP antibodies mouse mAb 384, mouse mAb 382, and rabbit pAb 980 were purchased from Chemicon International. Biotinylation of mAbs was carried out using EZ-Link Sulfo-NHS-LC-LC-biotin (Pierce, Rockford, IL) according to manufacturer's instructions.

Co-Immunoprecipitation Experiments

A β 42 peptides were resuspended in Me₂SO to 2.5 mM and used at 10.8 μ M. Purified MBP was used at 1.56 μ M. Proteins were combined in 250 μ l incubation buffer (PBS/0.05% Tween 20/1% BSA). Anti-MBP mAb 382 was added to each sample mixture and incubated for 1 h at 4°C with rocking. After incubation 20 μ l of washed GammaBind protein G Sepharose beads (Amersham) was added to each mixture, which then were incubated for an additional 1 h at 4°C with rocking.

For competitive co-immunoprecipitation experiments MBP was first immobilized to GammaBind beads at 1 μ g of MBP per 80 μ l of beads using mAb 382 and incubated for 1 h at 4°C in incubation buffer. Biotinylated A β 42WT peptide was resuspended in Me₂SO to 2.5 mM and used at 12.5 μ M. A β 40WT, and scrambled A42WT were resuspended in Me₂SO to 2.5 mM and used at 125 μ M. Proteins were combined with 20 μ l of washed MBP-immobilized beads and incubated for 1 h at 4°C with rocking.

For co-immunoprecipitations from brain homogenates ~200 μ g of brain cortical tissue from either human AD brain or one year old 5xFAD mice (28) were homogenized in 50 mM Tris, pH 7.4/200 mM NaCl plus Complete Protease Inhibitor (Roche) on ice. Aliquots received either approximately 400 μ g of anti-MBP polyclonal IgG, or no antibody as control. Aliquots were then incubated with 20 μ l of GammaBind protein G Sepharose beads for 1 h at 4°C with rocking.

After all the above incubations the beads were separated by centrifugation at $8,000 \times g$ for 2 min. Supernatants were removed and beads were washed with 1 ml of incubation buffer. Separation and washing were repeated three times. A final wash was performed in PBS/0.05% Tween 20 to remove excess BSA. Centrifuged beads were combined with 25 μ l of reducing SDS-PAGE sample loading buffer and heated. 10 μ l of each sample/loading buffer mix were loaded onto 10–20% Tricine gels (Invitrogen) and electrophoresed at 125 V for 90 min. Gels were transferred to Hybond ECL nitrocellulose membranes (Amersham Biosciences) at 50 V overnight at 4°C. Membranes were blocked in PBS containing 5% bovine serum albumin (BSA) at room temperature for 1 h and washed 3×10 min with 5% BSA/PBS and 0.05% Tween 20. Membranes were incubated with primary antibodies for 1 h where applicable and washed as described above. Next, the membranes were incubated with horseradish peroxidase-conjugated streptavidin (Amersham Biosciences) for 1 h and washed. Detection was accomplished using ECL Western blotting substrate (Pierce), Experiments were performed in triplicate.

Surface Plasmon Resonance

All runs were performed on a BiaCore 2000 instrument (Uppsala, Sweden) with 10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% (v/v) Tween 20 as running buffer and diluent. N-terminally biotinylated A β 42 peptides were resuspended in Me₂SO to 2.5 mM and serially diluted to 13 nM immediately before application. A β 42 was bound to flow cell 2 at 10 μ l/min to achieve an average relative response level of 157.1 RU leaving flow cell 1 as a reference. This chip preparation procedure was found to result in a surface that minimized mass transfer effects for kinetic interaction studies. The resultant $R_{\max}$ of this surface was

approximately 700 RU with both MBP and ECP as the analyte. Purified MBP was passed over both flow cells at 6.25, 12.5, 25, 50, and 100 nM, while ECP was run at 3.2, 1.6, 0.8, 0.4, and 0.2 μ M in triplicate at flow rates of 30 μ l/min for kinetic measurements. Faster flow rates did not significantly improve the quality of data. Surfaces were regenerated with 0.2 M glycine pH 2.0, 150 mM NaCl between runs. The resulting sensorgrams were analyzed by BiaCore Analysis software.

Circular Dichroism Spectroscopy

Lyophilized A β 42 peptides were first resuspended with 100 mM NaOH to 2.4 mM, diluted to 50 μ M in 10 mM potassium phosphate, pH 8.0/11 mM NaCl, and then incubated at 37°C either alone or with 6.25 μ M MBP. CD measurements from 190 nm to 260 nm were carried out using an Olis RSM 1000 CD Spectrophotometer (On-Line Instrument Systems, Bogart, GA). Six scans using adaptive acquisition timing were averaged for each sample using Olis software. The 1 mm quartz cuvettes used for sample data collection were cleaned between readings using 6N HCl followed by a methanol rinse.

Attenuated Total Reflection Infrared Spectroscopy

Lyophilized A β 42 peptides were first resuspended with 100 mM NaOH to 2.4 mM, diluted to 50 μ M in PBS and then incubated at 37°C either alone or with 6.25 μ M MBP. At the required timepoints 100 μ g of protein were dried onto an ATR plate and scanned using a Bruker IFS 66v/S infrared spectrometer. Spectra were recorded using 2000 scans over the range of 4000-400 cm^{-1} .

Thioflavin T Fluorescence Assay

Lyophilized A β 42 peptides were first resuspended with Me₂SO to 2.5 mM, diluted to 12.5 μ M in PBS, and then incubated at 37°C with rocking either alone, with 1.56 μ M MBP, or with 1.56 μ M bovine lactalbumin. Control samples containing 0.5% Me₂SO and 1.56 μ M MBP, or 1.56 μ M lactalbumin in PBS were also included. At each timepoint, 100 μ l samples of each reaction were placed in a 96-well microplate in triplicate and 5 μ l of 100 μ M thioflavin T was added. The plate was mixed and incubated at 22°C in the dark for 10 min. Fluorescence was measured at 490 nm using an excitation wavelength of 446 nm in a SpectraMax spectrofluorimeter (Molecular Devices, Sunnyvale, CA) using SoftMax Pro control software.

Transmission Electron Microscopy

Sample mixtures were deposited onto carbon-coated copper mesh grids (EM Sciences, Hatfield, PA) and negatively stained with 2% (w/v) uranyl acetate. The samples were viewed with a FEI Tecnai 12 BioTwin transmission electron microscope, and digital images were taken with an AMT camera.

Atomic Force Microscopy

AFM was carried out using a LifeScan controller developed by LifeAFM (Port Jefferson, NY) interfaced with a Digital Instruments (Santa Barbara, CA) MultiMode microscope fitted with an E scanner. AFM samples were first titrated to pH 4 using dilute HCl and then

adsorbed onto freshly cleaved ruby mica (S & J Trading, Glen Oaks, NY). The lower pH allows for better adsorption of A β 42 peptides to the negatively charged mica surface. Samples were imaged under hydrated conditions using super-sharp silicon probes (SSS-Cont, Nanosensors, Neuchatel, Switzerland) that were modified for magnetic retraction by attaching samarium cobalt particles (LifeAFM, Port Jefferson, NY). We estimate the effective diameter of the super-sharp silicon probes to be 4 ± 1 nm at a height of 2 nm. Data analysis and graphics was performed using Interactive Display Language 5.0 (Research Systems Inc., Boulder, CO). In the Z scale bars, numbers in each color square indicate the Z-value at the middle of the range for that color.

RESULTS

MBP interacts with fibrillogenic A β 42 peptide

Previously, we reported the interaction of MBP with a familial CAA mutant A β 40 peptide containing E22Q (Dutch) and D23N (Iowa) mutations (A β 40DI) (25). It was also shown that MBP could bind the A β 40WT peptide, but with significantly less affinity. Here, we demonstrate using co-immunoprecipitation that MBP also interacts with the longer, more fibrillogenic, A β 42WT peptide. Samples containing MBP alone, MBP and A β 42WT, or A β 42WT alone were incubated with anti-MBP mAb 382 and precipitated with protein G-coated beads (Fig. 1A). Duplicate immunoblot analyses were performed on each sample with either biotinylated anti-MBP mAb 384 or biotinylated anti-A β mAb 3D6. A β 42WT was precipitated only in the presence of MBP and was not pulled down in the absence of MBP. The specificity of the interaction between A β 42WT and MBP in this assay was examined by competition with an excess of A β 40WT and a scrambled A β 42WT peptide. A β 42WT was inhibited from binding to MBP only in the presence of excess A β 40WT and not in the presence of the scrambled A β 42WT peptide indicating that the interaction is specific (Fig. 1B). Densitometric analysis of the immunoblots from the competitive co-immunoprecipitation studies showed that excess A β 40WT inhibited the binding of A β 42WT to MBP by approximately 85% (Fig. 1C).

A β was immunoprecipitated from soluble cortical homogenates prepared from both human AD brain and 5xFAD mouse brain. This data indicates that MBP can interact with A β peptides at a sufficient strength to associate in the presence of a complex mixture of biomolecules in brain homogenate.

To more quantitatively analyze the affinity between MBP and A β 42, we next performed SPR measurements. A β 42WT peptide ligand surfaces and other assay parameters were designed as described in Materials and Methods. Increasing concentrations of MBP were passed over the ligand surface and the resultant sensorgrams were analyzed using BIAanalysis software. From this, the kinetics of the interactions were determined (Table 1). The calculated K_D between MBP and A β 42WT is comparable to the affinity between MBP and A β 40DI, and is stronger than that between MBP and A β 40WT as reported previously (25). Eosinophil cationic protein (ECP), which has a very similar charge and molecular mass compared to MBP, was used as a negative control to test the specificity of the MBP/A β 42WT interaction with SPR. No binding could be detected between the A β 42WT ligand surface and ECP at concentrations up to 32-fold greater than MBP. Further ECP did not

compete for MBP binding to A β 42 in co-immunoprecipitation experiments (data not shown).

MBP prevents the formation of β -sheet structures in A β 42WT in-vitro

After demonstrating the affinity between A β 42WT and MBP *in vitro* we next determined if this interaction could inhibit A β 42WT fibrillogenesis. The assembly of fibrils from A β monomers is accompanied by the formation of β -sheet secondary structure within and between individual monomers (29). Therefore, we sought to examine the effect of MBP on the secondary structure of A β 42WT using circular dichroism spectroscopy during fibrillogenesis.

First, we measured the time dependent CD spectra between 190–260 nm for A β 42WT, making scans at regular intervals from 0–36 h (Fig. 2A). At 0 h, the A β 42WT CD spectra displayed a characteristic negative peak at 197 nm, which correlates with the presence of abundant random-coil conformation. Over the course of 36 h, A β 42WT adopts a predominantly β -sheet conformation as shown by the emergence of a characteristic positive peak at 195 nm and a negative peak at 215 nm. Similar incubations were also performed on A β 42WT with MBP, as well as with MBP alone. Throughout the time-course, MBP exhibited a characteristic random-coil conformation (data not shown) as has been previously reported (30).

It has been shown that plotting the absolute value of the CD signal at 215 nm versus time produces a curve indicative of the formation of β -sheet fibrils over time for A β peptides (31). In Fig. 2B the absolute values of the CD ellipticity for both MBP alone and A β 42WT with MBP were compared to A β 42WT alone. These data illustrate that A β 42WT β -sheet formation proceeds linearly until 24 h where it begins to plateau. Conversely, for both MBP alone and A β 42WT with MBP the signal remained low and decreased somewhat over the course of incubation, suggesting a lack of β -sheet formation. At 48 h, a sample of A β 42WT, which demonstrated a high abundance of β -sheet, was spiked with MBP and scanned immediately (Fig. 2C). This was compared to a scan at 48 h of A β 42WT with MBP to illustrate the difference between a sample containing MBP in the presence of β -sheet structure, and a sample containing MBP and no β -sheet structure. These data suggest that MBP is able to inhibit the formation of β -sheet structures from unstructured A β 42WT monomers.

Attenuated total reflection (ATR) infrared spectroscopy was used to further examine the secondary structure of A β 42WT in the presence of MBP. The IR spectra of a protein, especially absorbance in the Amide I band (~ 1700 – 1600 cm^{-1}), is sensitive to changes in secondary structure (32–34). Spectra obtained for A β 42WT incubated at 37°C for 24 h had a main peak at 1635 cm^{-1} with a smaller shoulder peak at 1616 cm^{-1} which were assigned to major β -sheet structure. The peak at 1673 cm^{-1} is due to β -turn structure. When A β 42WT is incubated in the presence of MBP we measured two unresolved peaks at 1670 cm^{-1} and 1648 cm^{-1} assigned to β -turn and α -helical/unordered structures respectively (Fig 3A). The contributing peaks in the Amide I band however are overlapping and convoluted making interpretation of secondary structure difficult in many cases as it is with these data. By plotting the second-derivative of the spectra the contributing components can be resolved

and their relative contribution studied (32). When plotted in this manner it shows that both A β 42WT alone and A β 42WT with MBP contain identical peaks at 1681 cm⁻¹ and 1675 cm⁻¹ due to the presence of β -turn structure. A β 42WT with MBP shows two peaks at 1658 cm⁻¹ and 1650 cm⁻¹ assigned to α -helical and unstructured elements. Both samples with and without MBP have peaks of 1697 cm⁻¹ and 1616 cm⁻¹ in the β -sheet regions however the contribution is higher in the A β 42WT sample without MBP. A β 42WT alone also shows a strong β -sheet contribution at 1633 cm⁻¹ that is much larger than the peak at 1635 cm⁻¹ for A β 42WT with MBP. The signal at 1635 cm⁻¹ also is more shifted away from β -sheet and towards the α -helical and unstructured region of the band and contains unresolved α -helical and unstructured elements as well in its shoulder (Fig 3B). This confirms the CD measurements that show less β -sheet structure in A β 42WT in the presence of MBP.

This inhibitory affect was also confirmed by using a thioflavin T fluorescence assay. We found that an 8-fold lower molar concentration of MBP was sufficient to dramatically inhibit A β 42WT fibril formation (Fig. 4). No change in A β 42WT thioflavin T fluorescence was seen when performed in the presence of a similarly sized negative control protein (bovine lactalbumin) under these conditions.

MBP inhibits the formation of A β 42 fibrils

The inhibition of fibril assembly was further confirmed by TEM and single-touch AFM analysis. At 6 h of incubation in the absence of MBP, oligomeric structures become evident (Fig. 5). These oligomeric structures can reach lengths of up to 40 nm and heights of up to ~ 3.5 nm. By 24 h these oligomeric structures had assembled into fibrillar structures measuring several hundred nm in length with an average height of over 4 nm. In the presence of substoichiometric amounts of MBP, the formation of these structures was greatly reduced, indicating an inhibition of fibril formation by MBP.

DISCUSSION

A β 42WT is much more fibrillogenic than A β 40WT and has been shown to form different soluble and insoluble oligomeric forms than A β 40WT (35). Many of these A β 42WT oligomeric assemblies have been shown to be more cytotoxic than A β 40WT oligomeric assemblies (36–38) as well as acting as seeds for the formation of A β 40WT fibrils (9). A β 42WT levels in brain tissue have been shown to increase after head injury, possibly predisposing patients to AD-like symptoms (39). Mutations that result in a high likelihood of developing AD often result in an increase in A β 42WT production (40). For these reasons the role of A β 42WT has increasingly come under scrutiny in the pathology of AD and related disorders.

Previously, we have demonstrated that MBP binds to and inhibits the fibrillogenesis of familial CAA mutant forms of A β as well as its weaker ability to bind to A β 40WT (25). We hypothesized that this interaction may be a possible explanation for the regional differences seen in the deposition of fibrillar amyloid within the brains of patients and animal models with these familial CAA mutant forms of A β . Although we have begun to understand how MBP interacts with CAA mutant A β 40, it was not known whether a similar interaction would take place with the more fibrillogenic A β 42WT peptide.

In the present study we show that MBP can, in fact, bind to and inhibit the fibrillogenesis of A β 42WT peptide *in vitro*. Co-immunoprecipitation experiments (Fig. 1) demonstrate that A β 42WT interacts with MBP. This interaction was demonstrated to be specific by the failure of a scrambled A β 42WT peptide to compete with A β 42WT to bind with MBP and the competition of A β 40WT with this binding to MBP (Fig. 1B, C). Similarly, A β peptides were co-precipitated with MBP using a polyclonal antibody to MBP from cortical brain homogenates of human AD brain tissue or 5xFAD mouse brain, a transgenic mouse model that produces high levels of A β 42WT in its brain tissue (28). (Fig. 1D). Although it is not conclusive from this data alone whether MBP and A β normally associate *in-vivo* it does demonstrate that in the complex mixture of a brain homogenate the interaction between MBP and A β peptides is of sufficient specificity to facilitate co-precipitation.

Although A β 42WT does not contain either the Dutch or the Iowa mutations, it is highly fibrillogenic, suggesting that the interaction does not require the mutant residues at positions 22 and 23, but rather that MBP may be interacting with a certain conformation common to both A β 42WT and familial CAA mutant A β 40DI. Consistent with this idea affinity values for A β 42WT and MBP were also higher than those obtained for A β 40WT and MBP reported previously (25). A β 40WT is much less fibrillogenic than A β 42WT lending weight to the hypothesis that MBP is interacting with conformations more prevalent in suspensions of more fibrillogenic A β peptides. Further study will be necessary to elucidate the precise nature of these interactions.

By using CD spectroscopy we demonstrate that the interaction between MBP and A β 42WT resulted in a reduction in the adoption of β -sheet structure when compared to A β 42WT alone (Fig. 2). By plotting the absolute value at 215 nm for successive scans we were able to quantitate the emergence of β -sheet structure in our samples over time (Fig. 2B). We show that in the presence of MBP, which remains in a random coil conformation, A β 42WT is unable to form appreciable β -sheet structures.

To determine whether this failure to detect a β -sheet signature was due to signal quenching by MBP present in the sample, we performed a scan on mature (48 h) A β 42WT fibrils (as determined through CD analysis), which was spiked with MBP and immediately scanned. Comparisons of the signal obtained with this spiked control sample were compared to the signal obtained from a sample of A β 42WT incubated for 48 h with MBP (Fig. 2C). The spiked sample clearly showed the presence of β -sheet structures as evidenced by a negative peak at 215 nm. This was an indication that had the A β 42WT peptides formed β -sheet secondary structures in the presence of MBP, they would have been detected.

Further evidence for the inhibition of β -sheet structures was obtained through second-derivative ATR-IR analysis. In the presence of MBP the β -sheet contribution is much diminished though not completely extinguished suggesting an inhibition of larger β -sheet oligomers (Fig 3B). The typical β -hairpin loop structure of A β 42WT monomers contains anti-parallel β -sheet structure which if left intact would explain the small β -sheet structural component seen in the spectra of samples containing MBP. Further, the peaks at 1681 cm⁻¹ and 1675 cm⁻¹ which are attributed to β -turn structure remained unchanged even with the addition of MBP suggesting that the β -hairpin structure of A β 42WT is intact in the presence

of MBP. These data suggest that MBP is interacting with A β 42WT monomers in a manner that leaves their β -hairpin structure intact but inhibits the formation of larger β -sheet oligomers.

The inhibition of the formation of β -sheet oligomers and fibrils in A β 42WT by MBP is supported by thioflavin-T analysis, which demonstrates a lack of thioflavin-T fluorescence in samples containing A β 42WT and MBP (Fig. 4). This observation further indicates an inhibition of fibril formation by MBP. The rate of fibril formation in the thioflavin-T assay, when compared to the rate observed in the CD measurements, was much more rapid. A plateau in thioflavin-T fluorescence was reached at approximately 2 h, while samples measured by CD reached a plateau only after 12 h. This difference can be explained by the difference in the NaCl concentrations used for these experiments. The NaCl concentration was 150 mM in samples used for thioflavin-T measurements, while for CD spectroscopy the NaCl concentration was 11 mM. A lower salt concentration was used for CD experiments because high salt concentrations interfere with CD measurements between 190 nm – 210 nm.

These results are further supported by direct visualization of amyloid fibril assembly using both TEM and AFM at longer time points (Fig. 5). The formation of short oligomeric structures becomes evident at 6 h as detected by both AFM and TEM for A β 42WT alone. However, when MBP is present there appears to be a marked reduction in the presence of these structures. Upon continuous incubation of A β 42WT to 24 h larger fibrils are seen. By TEM these fibrils appear to range between 50 and 200 nm in length and are noticeably absent when MBP is present.

Our results indicate that MBP can interact with A β 42WT *in-vitro* and inhibit its fibrillogenesis. Previous studies have shown that MBP can bind to and inhibit the fibrillogenesis of the CAA double mutant A β 40DI peptide (25). Presently, it is unknown if MBP interacts with both peptides in a similar manner.

It has been shown that different A β peptides may assemble along different or multiple folding pathways giving rise to heterogeneous mixtures of structures whose ratios may be unique from peptide to peptide. Given the likely differences between the folding pathways of A β 40WT, A β 42WT, and A β 40DI, and that their affinity for MBP increases with rising fibrillization rate it may be possible that a subset of conformations favored by the more fibrillogenic peptides are responsible for the bulk of the interaction with MBP. In other words, A β 40WT suspensions may lack or have less of these specific conformations more common to A β 42WT and A β 40DI suspensions, explaining the lower affinity between MBP and A β 40WT and the higher affinity with A β 42WT and A β 40DI. Further study will be necessary to elucidate the molecular basis for the interaction between MBP and A β peptides.

However, this interaction raises intriguing questions as to what role MBP, or MBP related peptides, may exhibit in association with A β 42WT, and what role this interaction may play in the pathogenesis of AD and other related disorders. For instance, MBP may serve to suppress the deposition and seeding of amyloid plaques at their earliest stages of formation. Alterations in levels of intact MBP or derived fragments may affect how A β peptides are

retained or cleared from brain. It may also be possible that although MBP inhibits the formation of fibrils it may stabilize the formation of neurotoxic oligomers and thereby exacerbate disease pathology.

It is interesting to note that deposits of A β found in regions of white matter, which are rich in myelinated axons, are often diffuse and non-fibrillar (41, 42). Damage to white matter is known to result in an increase of myelin proteins and especially MBP related peptides in the cerebral spinal fluid (CSF) (43). Microglia have also been shown to secrete GOLLI-MBP proteins when activated (44, 45). This release of MBP into the extracellular environment in AD patients with white matter damage and/or activated microglia could provide ample opportunities for this interaction with A β to take place and inhibit the formation of fibrils, though further *in-vivo* study will be needed to confirm this. These findings point to the need to better understand the effect of changes in white matter as well as the role of MBP related peptides in the brain and how they relate to AD progression.

Abbreviations

Aβ	amyloid β -protein
AD	Alzheimer's disease
AβPP	amyloid β -protein precursor
CAA	cerebral amyloid angiopathy
Aβ40WT	wild-type A β 40 peptide
Aβ40DI	Dutch/Iowa cerebral amyloid angiopathy double mutant A β 40 peptide
MBP	myelin basic protein
Aβ42WT	wild-type A β 42 peptide
PBS	phosphate-buffered saline
BSA	bovine serum albumin
SDS-PAGE	sodium dodecyl sulfate-polyacrylamide gel electrophoresis
CD	circular dichroism
SPR	surface plasmon resonance
ECP	eosinophil cationic protein
ATR	attenuated total reflectance
TEM	transmission electron microscopy
AFM	atomic force microscopy
mAb	monoclonal antibody
CSF	cerebral spinal fluid

References

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev.* 2001; 81:741–766. [PubMed: 11274343]
2. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature.* 1987; 325:733–736. [PubMed: 2881207]
3. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. *Science.* 1987; 235:877–880. [PubMed: 3810169]
4. Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. *Science.* 1987; 235:880–884. [PubMed: 2949367]
5. Robakis NK, Ramakrishna N, Wolfe G, Wisniewski HM. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. *Proc Natl Acad Sci U S A.* 1987; 84:4190–4194. [PubMed: 3035574]
6. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ. beta-Amyloid-(1–42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. *Proc Natl Acad Sci U S A.* 1993; 90:10836–10840. [PubMed: 8248178]
7. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci U S A.* 1985; 82:4245–4249. [PubMed: 3159021]
8. Dolev I, Michaelson DM. The nucleation growth and reversibility of Amyloid-beta deposition in vivo. *J Alzheimers Dis.* 2006; 10:291–301. [PubMed: 17119294]
9. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. *Neuron.* 2005; 47:191–199. [PubMed: 16039562]
10. Findeis MA. The role of amyloid beta peptide 42 in Alzheimer's disease. *Pharmacol Ther.* 2007; 116:266–286. [PubMed: 17716740]
11. Vinters HV. Cerebral amyloid angiopathy. A critical review. *Stroke.* 1987; 18:311–324. [PubMed: 3551211]
12. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. *J Neural Transm.* 2002; 109:813–836. [PubMed: 12111471]
13. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. *J Neuropathol Exp Neurol.* 2003; 62:1287–1301. [PubMed: 14692704]
14. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GT, Luyendijk W, Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. *Science.* 1990; 248:1124–1126. [PubMed: 2111584]
15. Van Broeckhoven C, Haan J, Bakker E, Hardy JA, Van Hul W, Wehnert A, Vegter-Van der Vlis M, Roos RA. Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). *Science.* 1990; 248:1120–1122. [PubMed: 1971458]
16. Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, Warren A, McInnis MG, Antonarakis SE, Martin JJ, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. *Nat Genet.* 1992; 1:218–221. [PubMed: 1303239]
17. Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, Pulst SM, Anderson L, O'Dahl S, Nemens E, White JA, et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. *Am J Hum Genet.* 1992; 51:998–1014. [PubMed: 1415269]
18. Tagliavini F, Rossi G, Padovani A, Magoni M, Andora G, Sgarzi M, Bizzi A, Savioardo M, Carella F, Morbin M, Giaccone G, Bugiani O. A new APP mutation related to hereditary cerebral hemorrhage. *Alzheimer's Reports.* 1999; 2:S28.

19. Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. *Ann Neurol*. 2001; 49:697–705. [PubMed: 11409420]
20. Davis J, Van Nostrand WE. Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. *Proc Natl Acad Sci U S A*. 1996; 93:2996–3000. [PubMed: 8610157]
21. Verbeeck MM, de Waal RM, Schipper JJ, Van Nostrand WE. Rapid degeneration of cultured human brain pericytes by amyloid beta protein. *J Neurochem*. 1997; 68:1135–1141. [PubMed: 9048759]
22. Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, Frangione B, Ghiso J. Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. *J Biol Chem*. 2000; 275:27110–27116. [PubMed: 10821838]
23. Melchor JP, McVoy L, Van Nostrand WE. Charge alterations of E22 enhance the pathogenic properties of the amyloid beta-protein. *J Neurochem*. 2000; 74:2209–2212. [PubMed: 10800967]
24. Van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW. Pathogenic effects of D23N Iowa mutant amyloid beta -protein. *J Biol Chem*. 2001; 276:32860–32866. [PubMed: 11441013]
25. Hoos MD, Ahmed M, Smith SO, Van Nostrand WE. Inhibition of familial cerebral amyloid angiopathy mutant amyloid beta-protein fibril assembly by myelin basic protein. *J Biol Chem*. 2007; 282:9952–9961. [PubMed: 17259179]
26. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. *J Biol Chem*. 1992; 267:546–554. [PubMed: 1730616]
27. Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. *J Biol Chem*. 2003; 278:11612–11622. [PubMed: 12499373]
28. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. *J Neurosci*. 2006; 26:10129–10140. [PubMed: 17021169]
29. Nelson R, Eisenberg D. Recent atomic models of amyloid fibril structure. *Curr Opin Struct Biol*. 2006; 16:260–265. [PubMed: 16563741]
30. Harauz G, Ishiyama N, Hill CM, Bates IR, Libich DS, Fares C. Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. *Micron*. 2004; 35:503–542. [PubMed: 15219899]
31. Bartolini M, Bertucci C, Bolognesi ML, Cavalli A, Melchiorre C, Andrisano V. Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. *Chembiochem*. 2007; 8:2152–2161. [PubMed: 17939148]
32. Susi H, Byler DM. Protein structure by Fourier transform infrared spectroscopy: second derivative spectra. *Biochem Biophys Res Commun*. 1983; 115:391–397. [PubMed: 6615537]
33. Haris PI, Chapman D. Analysis of polypeptide and protein structures using Fourier transform infrared spectroscopy. *Methods Mol Biol*. 1994; 22:183–202. [PubMed: 8312993]
34. Jackson M, Mantsch HH. The use and misuse of FTIR spectroscopy in the determination of protein structure. *Crit Rev Biochem Mol Biol*. 1995; 30:95–120. [PubMed: 7656562]
35. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. *Proc Natl Acad Sci U S A*. 2003; 100:330–335. [PubMed: 12506200]
36. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N, Sato K. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/ glycogen synthase kinase-3beta. *Proc Natl Acad Sci U S A*. 2003; 100:6370–6375. [PubMed: 12750461]
37. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. *J Neurochem*. 2007; 101:1172–1184. [PubMed: 17286590]
38. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta peptide. *Nat Rev Mol Cell Biol*. 2007; 8:101–112. [PubMed: 17245412]

39. DeKosky ST, Abrahamson EE, Ciallella JR, Paljug WR, Wisniewski SR, Clark RS, Ikonomic MD. Association of increased cortical soluble abeta42 levels with diffuse plaques after severe brain injury in humans. *Arch Neurol*. 2007; 64:541–544. [PubMed: 17420316]
40. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. *Neuron*. 1996; 17:1005–1013. [PubMed: 8938131]
41. Behrouz N, Defossez A, Delacourte A, Mazzuca M. The immunohistochemical evidence of amyloid diffuse deposits as a pathological hallmark in Alzheimer's disease. *J Gerontol*. 1991; 46:B209–212. [PubMed: 1719062]
42. Wisniewski HM, Bancher C, Barcikowska M, Wen GY, Currie J. Spectrum of morphological appearance of amyloid deposits in Alzheimer's disease. *Acta Neuropathol*. 1989; 78:337–347. [PubMed: 2551122]
43. Whitaker JN. Myelin basic protein in cerebrospinal fluid and other body fluids. *Mult Scler*. 1998; 4:16–21. [PubMed: 9532587]
44. Papenfuss TL, Thrash JC, Danielson PE, Foye PE, Hillbrush BS, Sutcliffe JG, Whitacre CC, Carson MJ. Induction of Golli-MBP expression in CNS macrophages during acute LPS-induced CNS inflammation and experimental autoimmune encephalomyelitis (EAE). *ScientificWorldJournal*. 2007; 7:112–120. [PubMed: 17982583]
45. Filipovic R, Zecevic N. Lipopolysaccharide affects Golli expression and promotes proliferation of oligodendrocyte progenitors. *Glia*. 2005; 49:457–466. [PubMed: 15546149]

FIGURE 1.

Co-immunoprecipitation of MBP and Aβ42WT. **A.** Aβ42WT peptide was co-immunoprecipitated with MBP using anti-MBP mAb 382 as described in “Materials and Methods.” Immunoprecipitated samples from left to right: MBP alone, Aβ42WT alone, MBP incubated with Aβ42WT, negative control (no MBP/no Aβ42WT). **B.** Representative immuoblot showing the co-immunoprecipitation of biotinylated Aβ42WT with MBP was effectively competed with excess Aβ40WT peptide but not excess scrambled Aβ42WT peptide. **C.** Quantitation of the competitive co-immunoprecipitation assays. The data presented are the mean ± S.D. of triplicate experiments (**p* < 0.001). **D.** Immunoprecipitation from soluble cortical brain homogenates of human AD brain and 5xFAD mouse brain using polyclonal anti-MBP IgG. Immunoprecipitations from left to right are: 5xFAD mouse brain, human AD brain, 5xFAD control, and human AD control.

FIGURE 2.

Inhibition of A β 42WT β -sheet formation by MBP, assessed by CD spectroscopy. Peptides were prepared and scanned as described in "Materials and Methods." **A.** Successive scans of A β 42WT incubated at 37°C taken at 0 (■), 6 (■), 12 (■), 24 (■), 36 (■). **B.** Absolute values at 215nm charted from successive scans. A β 42 (■), MBP (■), A β 42 with MBP (■). **C.** Single scan of A β 42WT with MBP at 48h (black) compared to a single scan of mature A β 42WT fibrils spiked with MBP at 48h (gray).

FIGURE 3.

Inhibition of A β 42WT β -sheet formation by MBP assessed by ATR-IR. Peptides were prepared and scanned as described in “Materials and Methods.” **A.** IR absorbance in the Amide I band for A β 42WT alone (black line) or with MBP (gray line) incubated at 37°C at 24h. **B.** Second-derivative plot of IR spectra in **A.**

FIGURE 4.

Thioflavin T analysis for inhibition of A β 42WT fibril formation by MBP. A β 42 was treated with HFIP, resuspended to a concentration of 2.5 mM in DMSO, and then diluted to a concentration of 12.5 μ M in PBS in the absence (◇) or presence of 1.56 μ M MBP (△) or 1.56 μ M α -lactalbumin (□) as control. At specific timepoints aliquots were collected from each sample and subjected to thioflavin T binding and fluorescence to determine fibrillar assembly as described in “Materials and Methods”. The data shown are the mean $\pm$ S.D. of triplicate samples.

FIGURE 5.

AFM and TEM images of the inhibition Aβ42WT fibril formation by MBP. Aβ42WT samples were incubated at 37°C in the absence (top row) or presence (bottom row) of MBP at the same ratio of Aβ42WT:MBP used in the thioflavin T analysis. AFM images were scanned at 6 h and 24 h of incubation. EM images were taken at 24 h of incubation.

Table 1Binding affinities (KD) of MBP and ECP for A β peptides.

	MBP (M)	ECP(M)
A β 40DI	$1.69 \pm 0.14 \times 10^{-8}$	not detected
A β 42WT	$4.29 \pm 0.28 \times 10^{-8}$	not detected
A β 40WT	$1.16 \pm 0.12 \times 10^{-7}$	not detected